Compare Neurocrine Biosciences Inc (NBIX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sibanye Stillwater Ltd — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Sibanye Stillwater Ltd for 51 Days on average.
| NBIX | SBSW | |
|---|---|---|
Market Cap | $14.36B | $6.88B |
Volume | 1,237,180 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $21.12 |
52-Week Low | $123.10 | $8.00 |
Typical Hold Time | 23 Days | 51 Days |
Enterprise Value | $14.37B | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
SBSW trades at $9.91, up 2.38% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% EBITDA increase, driving positive sentiment.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying 44% upside, supported by operational improvements and commodity price strength. Risks include volatile earnings, high debt levels, and exposure to commodity cycles. Upside hinges on sustained execution of the growth roadmap and cost discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
